A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Phase 2
120
about 3.2 years
18–130
14 sites in AZ, CA, DC +11
About this study
This trial is testing the safety and effectiveness of new treatments for colorectal cancer. Participants will be randomly assigned to receive different combinations of medications, including Volrustomig, FOLFIRI (a chemotherapy drug), and Bevacizumab (an anti-cancer drug). It aims to evaluate how well these interventions work in people with advanced or metastatic colorectal cancer who have not received previous treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Bevacizumab
- 2.Take FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
- 3.Take Volrustomig
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bevacizumab, chemotherapy (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions)
infusion, injection (Injection), oral (Oral Capsule)
Primary: Number of Participants with Adverse Events (AEs), Progression Free Survival (PFS)
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Maximum Observed Concentration (Cmax), Objective Response Rate (ORR), Overall Survival (OS), Time to second progression or death (PFS2)
Oncology